Novo Nordisk 2022: Expanding capabilities – PharmaLive
New GLP-1 weight loss drugs are about to ship to more American homes
Novo Nordisk's insulin pen receives EU approval to treat type 2 diabetes
GLP-1 franchise powers progress at Novo Nordisk in 2021
FDA approves Novo Nordisk's GLP-1 drug Rybelsus for first-line type 2 diabetes treatment
Another Weight-Loss Trial Win for Weekly GLP-1 Drug | MedPage Today
The 411 on a GLP-1
The Now Generation & New Generation of GLP-1 RAs: Reshaping the Care of T2DM
Glucagon-Like Peptide-1 (Glp-1) Analogs Market will generate new growth opportunities 2022-2028 | Novo Nordisk, Eli-Lilly and Company | Medgadget
A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity | Fierce Pharma
GLP-1: The Reliable Partner | circulatory system | GLP-1 is your reliable partner in treating type 2 diabetes. They work by mimicking the functions of natural incretin hormones -- including stimulating... | By Novo Nordisk | Facebook
GLP-1 diabetes drugs are being released one after another
Novo Nordisk promotes new GLP-1 receptor agonist to fight diabetes, obesity < Pharma < Article - KBR
Good News About GLP-1 Drugs and Cardiovascular Health - Type 2 Nation
First Oral GLP-1 Receptor Agonist Approved for Type 2 Diabetes - MPR
FDA approves Novo Nordisk's semaglutide for weight management - Drug Discovery and Development
